Middleby Corp (MIDD) Misses Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BTIG Starts bluebird bio (BLUE) at Buy
March 1, 2016 7:02 AM ESTBTIG initiated coverage on bluebird bio (NASDAQ: BLUE) with a Buy rating and a price target of $72.00.
Analyst Dane Leone said, "BLUE has underperformed the Nasdaq Biotech Index over the past 12 months as disappointing clinical development updates compounded valuation compression within the sector.... More
BlueBird Bio (BLUE) Post Quarter Update: Starbeam Trial Interim at AAN Next - Leerink
February 29, 2016 7:07 AM ESTLeerink Partners analyst, Jonathan Chang sees bluebird bio (NASDAQ: BLUE) gene therapy LentiGlobin as the key value driver for the stock with initial clinical proof-of-concept (POC) achieved in hemoglobinopathies and next clinical updates expected at the ASH annual meeting in Dec. Near term, positive Lenti-D interim Ph II/III data in ultra-rare Childhood Cerebral Adrenoleukodystrophy (CCALD) at the American Academy of Neurology (AAN) annual meeting (April 15-21) could represent important platform validation.
CCALD is a rare severe and progressive central nervous system (CNS) disease. While... More
